Home » Newsletters » BioWorld Science

BioWorld Science

May 5, 2022

View Archived Issues

Shujing Biopharma, Jiangsu Nhwa Pharmaceutical patent 5-HT2A/DRD2 antagonists

Vertex Pharmaceuticals describes new CFTR modulators

New K(Ca) 1.1 channel activators identified at Gwangju Institute of Science and Technology

Dana-Farber Cancer Institute synthesizes SRPK1/SRPK2 inhibitors

Merck & Co. discovers diacylglycerol acyltransferase type 2 inhibitors

M1 mAChR antagonism attenuates opioid drug seeking behaviors in rat

TRAIL protein levels may predict response to acamprosate in alcohol use disorder

CDK7 inhibitor GTAEXS-617 shows potent antitumor activity in vivo

FDA awards orphan drug designation to AB-001 for pancreatic cancer and AML

ALTA-2530 shows preclinical efficacy as potential treatment of bronchiolitis obliterans syndrome

DGKk gene therapy rescues brain lipid profiles and long-term behavior in fragile X syndrome mice

Researchers discover HDAC1 as the cause of immune abnormalities in autistic mouse models

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...